切换至 "中华医学电子期刊资源库"
高级检索
中华腔镜泌尿外科杂志(电子版)

中华腔镜泌尿外科杂志(电子版) ›› 2019, Vol. 13 ›› Issue (06) : 374 -377. doi: 10.3877/cma.j.issn.1674-3253.2019.06.004

所属专题： 经典病例； 经典病例； 文献；

病例研究·（最强挑战赛优秀病例）

一例寡转移前列腺癌患者基于循证医学的多学科综合诊治报告
王进有1, 谢栋栋1, 毕良宽1, 王毅1, 于德新1,†()   
  1. 1. 230601　合肥，安徽医科大学第二附属医院泌尿外科
  • 收稿日期:2019-03-01 出版日期:2019-12-01
  • 通信作者: 于德新
  • 基金资助:
    安徽省自然科学基金(1608085QH173); 安徽医科大学第二附属医院科技新星培优计划项目(2018KA01)

The multidisciplinary management of oligometastatic prostate cancer: a case report and review of literatures

Jinyou Wang1, Dongdong Xie1, Liangkuan Bi1, Yi Wang1, Dexin Yu1,†()   

  1. 1. Department of Urology, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China
  • Received:2019-03-01 Published:2019-12-01
  • Corresponding author: Dexin Yu
  • About author:
    Corresponding author: Yu Dexin, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

王进有, 谢栋栋, 毕良宽, 王毅, 于德新. 一例寡转移前列腺癌患者基于循证医学的多学科综合诊治报告[J]. 中华腔镜泌尿外科杂志(电子版), 2019, 13(06): 374-377.

Jinyou Wang, Dongdong Xie, Liangkuan Bi, Yi Wang, Dexin Yu. The multidisciplinary management of oligometastatic prostate cancer: a case report and review of literatures[J]. Chinese Journal of Endourology(Electronic Edition), 2019, 13(06): 374-377.

目的

探讨基于循证医学寡转移前列腺癌的综合治疗模式，以期延长患者生存时间。

方法

回顾性分析一例在我院行多学科协作诊治的寡转移前列腺癌患者临床资料，复习相关文献并予以讨论。

结果

患者初诊PSA为60 μg/L，盆腔MRI考虑前列腺癌，双侧精囊受侵，左侧输尿管口受侵，全身骨扫描可见四处骨转移，前列腺穿刺活检诊断为前列腺腺泡癌，Gleason评分4+5=9分。患者自2016年5月起以雄激素剥夺治疗为基础，先后序贯行新辅助化疗、减瘤性根治性前列腺切除术、立体定向放疗、阿比特龙+泼尼松治疗及再次多西他赛化疗，随访至2018年12月，患者无明显疼痛不适，但PSA升高，出现新发骨转移灶。

结论

循证医学给此类患者治疗选择带来更多的依据，多学科治疗模式可延长寡转移前列腺癌患者生存时间，改善生活质量。

关键词: 寡转移, 前列腺癌, 多学科, 综合治疗
Objective

To discussion the application of multidisciplinary comprehensive diagnosis and treatment of oligometastatic prostate cancer.

Methods

The clinical data of an oligometastatic prostate cancer patient treated with multidisciplinary comprehensive mode was analyzed retrospectively, and related literatures were reviewed.

Results

PSA of the patient was 60 μg/L. The pelvic MRI considered to be prostate cancer with bilateral seminal vesicle and left ureteral orifice invasion, diagnosis was confirmed by prostate biopsy and the Gleason score was 4+5, ECT scan found four bone metastases. The patient had been treated with androgen deprivation therapy since May 2016. He had undergone sequential neoadjuvant chemotherapy, cytoreductive radical prostatectomy, stereotactic radiotherapy, abiraterone + prednisone and Docetaxel chemotherapy. After follow-up until December 2018, the patient had no significant pain and discomfort, but the PSA increased.

Conclusion

Multidisciplinary treatment can prolong survival and improve quality of life in patients with oligometastatic prostate cancer.

Key words: Oligometastasis, Prostate cancer, Multidisciplinary, Synthetic therapy
图1 患者初诊时前列腺MRI及全身骨扫描检查
图2 寡转移前列腺癌患者综合治疗过程中tPSA变化图
[1]
Siddique O, Yoo ER, Perumpail RB, et al. The importance of a multidisciplinary approach to hepatocellular carcinoma[J]. J Multidiscip Healthc. 2017, 10: 95-100.
[2]
Tosoian JJ, Gorin MA, Ross AE, et al. Oligometastatic prostate cancer definitions, clinicail outcomes, and treatment considerations[J]. Nat Rev Urol, 2017, 14(1): 15-25.
[3]
Gupta A, Pugh TJ, Lam E, et al. The role of primary tumor treatment and metastasis-directed therapy in oligometastatic prostate cancer[J]. Oncology (Williston Park), 2019, 33(5): 187-191.
[4]
Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study[J]. Eur Urol, 2014, 65(6): 1058-1066.
[5]
Rusthoven CG, Jones BL, Flaig TW, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer[J]. J Clin Oncol, 2016, 34(24): 2835-2842.
[6]
Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study[J]. J Urol, 2015, 193(3): 832-838.
[7]
Vale Cl, Burdeet S, Rydzewska, et al. Addition of docetaxel OR bisphosphonates to standard of care in men with localized OR metastatic, hormone-sensitive prostate cancer a systematic review and meta-analyses of aggregate date[J]. Lancet Oncol, 2016, 17(2): 243-256.
[8]
Chi KN, Chowdhury S, Radziszewski P, et al. TITAN: a randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)[J]. Ann Oncol, 2016, 27(Suppl 6): vi243-265.
[9]
McClintock TR, von Landenberg N, Cole AP, et al. Neoadjuvant androgen deprivation therapy prior to radical prostatectomy: recent trends in utilization and association with postoperative surgical margin status[J]. Ann Surg Oncol, 2019, 26(1): 297-305.
[10]
Ost P, Bossi A, Decaestecker K, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature[J].2015, 67(5): 852-863.
[11]
Kim J, Park JS, Ham WS. The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer[J]. Investig Clin Urol, 2017, 58(5): 307-316.
[12]
潘家强，覃展偶. 去势抵抗性前列腺癌的临床治疗进展与处理策略[J/CD]. 中华腔镜泌尿外科杂志（电子版）, 2018, 12(1): 67-70.
[13]
de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer[J]. N EngL J Med, 2011, 364(21): 1995-2005.
[14]
Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer[J]. Eur Urol, 2017, 71(4): 630-642.
[15]
周祥福. 2018版欧洲泌尿外科前列腺癌指南要点解读[J/CD]. 中华腔镜泌尿外科杂志（电子版）, 2018, 12(5): 289-294.
[1] 方晔, 谢晓红, 罗辉. 品管圈在提高前列腺癌穿刺检出率中的应用[J]. 中华医学超声杂志（电子版）, 2023, 20(07): 722-727.
[2] 曹建辉, 徐栋, 冯斌, 郑俊彪, 黄伟伟. 超声造影在不同前列腺特异抗原含量前列腺癌穿刺活检中的应用价值[J]. 中华医学超声杂志（电子版）, 2023, 20(03): 307-312.
[3] 江文诗, 何湘湘. 全球及我国器官捐献发展特征分析与学科建设[J]. 中华移植杂志(电子版), 2023, 17(05): 280-286.
[4] 李全喜, 唐辉军, 张健生, 杨飞. 基于MUSE-DWI与SS-DWI技术在前列腺癌图像中的对比研究[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 553-557.
[5] 梅津熠, 王燕, 瞿旻, 董振阳, 周增辉, 沈显琦, 李嘉伦, 高旭. 机器人前列腺癌根治术中"膀胱外中叶"的处理[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 429-433.
[6] 穆靖军, 马增妮, 曹晓明. 临床局限性前列腺癌包膜外侵犯的危险因素分析[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(04): 326-331.
[7] 李全喜, 唐辉军, 唐友杰, 杨飞. DISCO成像技术在前列腺增生与前列腺癌鉴别诊断中的应用价值[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(04): 332-335.
[8] 王邦郁, 陈晓鹏, 唐国军, 王佳妮. 尿液细胞外囊泡circRNA分类器对高级别前列腺癌诊断价值的初步研究[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(04): 339-342.
[9] 刘硕儒, 王功炜, 张斌, 李书豪, 胡成. 新型溶瘤病毒M1激活内质网应激致前列腺癌细胞凋亡的机制[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(04): 388-393.
[10] 南方护骨联盟前列腺癌骨转移专家组. 前列腺癌骨转移诊疗专家共识（2023版）[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(03): 201-208.
[11] 吴晨瑞, 廖锐, 贺强, 潘龙, 黄平, 曹洪祥, 赵益, 王永琛, 黄俊杰, 孙睿锐. MDT模式下肝动脉灌注化疗联合免疫靶向治疗肝细胞癌多处转移一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 713-716.
[12] 何传超, 肖治宇. 晚期肝癌综合治疗模式与策略[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 486-489.
[13] 杨聚荣. 透析患者妊娠的管理[J]. 中华肾病研究电子杂志, 2023, 12(05): 300-300.
[14] 姜里蛟, 张峰, 周玉萍. 多学科诊疗模式救治老年急性非静脉曲张性上消化道大出血患者的临床观察[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 520-524.
[15] 王苏贵, 皇立媛, 姜福金, 吴自余, 张先云, 李强, 严大理. 异质性细胞核核糖蛋白A2B1在前列腺癌中的作用及其靶向中药活性成分筛选研究[J]. 中华临床医师杂志(电子版), 2023, 17(06): 731-736.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号